<DOC>
	<DOCNO>NCT00748826</DOCNO>
	<brief_summary>The goal study implement instrument would increase treat physician 's awareness necessary tuberculosis screen start new patient infliximab ( Remicade ) therapy react sufficiently disease-modifying preparation , include methotrexate .</brief_summary>
	<brief_title>Remicade Safety Line ( Study P03236 ) ( COMPLETED )</brief_title>
	<detailed_description>This study use non-probability sample method .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients active rheumatoid arthritis confirm adequate clinical response ( ACR ) criterion react sufficiently diseasemodifying preparation , include methotrexate , receive new treatment infliximab . As per Summary Product Characteristics ( SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>